Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note published on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Price Performance

NASDAQ:MRNS opened at $0.55 on Wednesday. The company’s 50-day moving average is $0.55 and its two-hundred day moving average is $0.73. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $9.24. The firm has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its position in Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares during the period. Franklin Resources Inc. raised its holdings in Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after buying an additional 1,219,871 shares during the period. Deltec Asset Management LLC acquired a new position in Marinus Pharmaceuticals in the fourth quarter valued at about $107,000. Jacobs Levy Equity Management Inc. boosted its stake in Marinus Pharmaceuticals by 39.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 117,255 shares during the period. Finally, Suvretta Capital Management LLC boosted its stake in Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after buying an additional 1,253,901 shares during the period. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.